Clinical Trials
47 trialsTraveraRTGx
Travera Inc
MK-4700-001
Merck Sharp & Dohme LLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
AYAConnect
UNC Lineberger Comprehensive Cancer Center
ARC-12
Arcus Biosciences, Inc.
EARN
Washington University School of Medicine
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
ROOT
Taproot Health
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
AstraZeneca
DUET-3
Xencor, Inc.
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Genmab
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
DUET-4
Xencor, Inc.
A Study of PRT1419 in Patients With Advanced Solid Tumors
Prelude Therapeutics
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
GASVERT
Institut de Cancérologie de Lorraine
DUET-2
Xencor, Inc.
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
Rutgers, The State University of New Jersey
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Jonsson Comprehensive Cancer Center
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
Herlev and Gentofte Hospital
Ensuring Communication in Hospice by Oncology Study (ECHO)
Massachusetts General Hospital
Collecting Tumor Samples From Patients With Gynecological Tumors
GOG Foundation
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children
University of Washington
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Memorial Sloan Kettering Cancer Center
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
OHSU Knight Cancer Institute
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Memorial Sloan Kettering Cancer Center
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
Hoag Memorial Hospital Presbyterian
The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients
Netherlands Open University
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation